HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: EJE-08-0578v1 159/6/811    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Bleicken, B. Articles by Quinkler, M. Search for Related Content PubMed PubMed Citation Articles by Bleicken, B. Articles by Quinkler, M.

Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens

Clinical Endocrinology, Charité Campus Mitte, Charité University Medicine Berlin, Charitéplatz 1, D 10117 Berlin, Germany¹ Endocrinology and Diabetes Unit, Department of Medicine I, University of Wuerzburg, 97080 Wuerzburg, Germany

(Correspondence should be addressed to M Quinkler; Email: marcus.quinkler{at}charite.de)

^* (B Bleicken and S Hahner contributed equally to this work)

Context: Recent studies have suggested that current glucocorticoid replacement therapies fail to fully restore well-being in patients with adrenal insufficiency (AI).

Objective: To investigate the effect of different glucocorticoid preparations used for replacement therapy on subjective health status (SHS) in AI.

Design and patients: In a cross-sectional study, primary and secondary AI patients were contacted by mail. Individual glucocorticoid replacement regimens, underlying diagnoses and comorbidities were verified by questionnaires and review of medical records. Patients were asked to complete three validated self-assessment questionnaires (Short Form 36 (SF-36), Giessen Complaint List (GBB-24), and Hospital Anxiety and Depression Scale). Results were compared with sex- and age-matched controls drawn from the questionnaire-specific reference cohort.

Results: Of the 883 patients identified, 526 agreed to participate in the study. Completed questionnaire sets were available from 427 patients (primary AI n=232; secondary AI n=195). AI patients showed significantly impaired SHS compared with controls irrespective of the glucocorticoid used for replacement. The only difference in SHS between patients on prednisolone (PR) and hydrocortisone (all patients and sub-analysis for primary AI) was significant higher bodily pain (lower Z-score in SF-36) in patients on PR (P<0.05, P<0.01 respectively). In patients with secondary AI, the PR group showed significantly (P<0.05) less heart complaints (lower Z-score) in the GBB questionnaire compared with the cortisone acetate group.

Conclusions: Glucocorticoid replacement therapy with PR seems to be equivalent to hydrocortisone regarding SHS in patients with AI. However, SHS remains impaired in all patient groups suggesting a need for further improved glucocorticoid replacement strategies.

This article has been cited by other articles:

				M. M. Erichsen, K. Lovas, B. Skinningsrud, A. B. Wolff, D. E. Undlien, J. Svartberg, K. J. Fougner, T. J. Berg, J. Bollerslev, B. Mella, et al. Clinical, Immunological, and Genetic Features of Autoimmune Primary Adrenal Insufficiency: Observations from a Norwegian Registry J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4882 - 4890. [Abstract] [Full Text] [PDF]

				W. Arlt The Approach to the Adult with Newly Diagnosed Adrenal Insufficiency J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1059 - 1067. [Abstract] [Full Text] [PDF]